ADRENALINE 1 mg/10 ml (1:10,000) solution for injection in pre-filled syringe
- Name:
ADRENALINE 1 mg/10 ml (1:10,000) solution for injection in pre-filled syringe
- Company:
Aguettant Ltd
- Active Ingredients:
- Legal Category:
Product subject to medical prescription which may not be renewed (A)
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 29/10/19
(Click to Download)Click on this link to Download PDF directly
Aguettant Ltd
Company Products
| Medicine Name | Active Ingredients |
|---|---|
| Medicine Name ADRENALINE 1 mg/10 ml (1:10,000) solution for injection in pre-filled syringe | Active Ingredients Adrenaline tartrate |
| Medicine Name Atropine Sulfate Aguettant 0.1 mg/ml solution for injection in pre-filled syringe | Active Ingredients Atropine Sulfate Monohydrate |
| Medicine Name Atropine Sulfate Aguettant 0.2 mg/ml solution for injection in pre-filled syringe | Active Ingredients Atropine Sulfate Monohydrate |
| Medicine Name Ephedrine Hydrochloride 3 mg/ml solution for injection in pre-filled syringe | Active Ingredients Ephedrine Hydrochloride |
| Medicine Name Murexal 10 mg/mL solution for injection in pre-filled syringe | Active Ingredients Suxamethonium Chloride |
| Medicine Name NORADRENALINE (NOREPINEPHRINE) 0.08 mg/ml, solution for infusion | Active Ingredients Noradrenaline tartrate |
| Medicine Name PHENYLEPHRINE 50 micrograms/ml, solution for injection in pre-filled syringe | Active Ingredients Phenylephrine Hydrochloride |
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 29 October 2019 PIL
Reasons for updating
- Change to section 2 - what you need to know - contraindications
Updated on 29 October 2019
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
Free text change information supplied by the pharmaceutical company
Section 4.4: Inclusion of further information regarding sodium.
Section 4.8: addition of new undesirable effect - Takotsubo cardiomypathy
Updated on 9 March 2018 SPC
Reasons for updating
- Change to section 6.3 - Shelf life
- Change to section 10 - Date of revision of the text
- Change to section 6.4 - Special precautions for storage
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 9 March 2018
Reasons for updating
- New SmPC for new product
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 25 July 2016 SPC
Reasons for updating
- New SPC for new product
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 5 April 2016 PIL
Reasons for updating
- New PIL for new product